Cascade Technologies Corp. (OTCBB: CSDT) announced today that Dr. Daniel L. Farkas, Chairman and CEO of Spectral Molecular Imaging (SMI), CSDT's wholly-owned subsidiary, delivered a keynote lecture at the International Joint Congress of the Minimally Invasive Spine Society and the International Musculoskeletal Lasers Society (IMLAS).
The conference was held in Antalya, Turkey (November 4-7), and was attended by 170 experts from four continents: surgeons, scientists, and healthcare specialists. This was the yearly meeting for IMLAS, an interdisciplinary surgical society for which Dr. Farkas is also the current President. He was elected to the position in 2008, when he was Vice-chair for Research, Professor and Director of the Minimally Invasive Surgical Technologies Institute at the Department of Surgery, Cedars-Sinai Medical Center in Los Angeles.
The keynote presented by Dr. Farkas was entitled Optical Imaging, Robotics and the Operating Room of the Future: New Strategies, Technologies and Alliances. It provided an overview of current state-of-the-art in high-tech imaging and neurosurgical intervention, and a map for future endeavors, including robotics and technologies developed by SMI.
“International conferences that focus on major areas such as spine surgery are critical in charting the future and promoting collaborations,” said Dr. Farkas, “and it is important to represent and articulate at such conferences interdisciplinary viewpoints that are based on using advanced technologies, some of which are just now making their way into clinical practice.”
About Spectral Molecular Imaging
Spectral Molecular Imaging, Inc., a wholly-owned subsidiary of Cascade Technologies Corp., is a development-stage medical imaging device company, applying its proprietary hyperspectral imaging technology, originally developed for satellite reconnaissance, to advance the early and accurate diagnoses of cancer and precancerous conditions. SMI is developing non-invasive, high-resolution optical imaging systems using its patented technology and other proprietary knowhow for improved clinical diagnostics, primarily in the field of cancer pathology, by identification and analysis of certain molecular, cellular, and tissue features. We expect to provide services related to our primary products, including software modules and maintenance services, and to develop optical diagnostic products that operate in conjunction with surgical and/or evaluation procedures in real time. We believe that our technology will enable early detection and more reliable diagnosis of various diseases, such as melanoma, Barrett’s esophagus (that can lead to esophageal cancer) and lung cancer. We expect that medical devices using or based on our developed technology can significantly improve long-term patient outcomes and may substantially reduce overall costs for the healthcare system. For more information, please visit http://www.spectralmi.com.
This news announcement contains or may contain certain "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, without limitation, statements regarding SMI's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects", "may", "could", "would", "should", "believes", "expects", "anticipates", "estimates", "intends", "plans" or similar expressions. Such forward-looking statements are subject to significant risks and uncertainties, including those detailed in filings made by Cascade Technologies Corp., SMI's parent, with the Securities and Exchange Commission. Accordingly we caution our readers that actual results may differ materially from our beliefs or expectations due to economic, business, competitive, market and regulatory factors. We assume no obligation or undertaking to update any forward-looking statements to reflect any changes in expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. You should, however, review additional disclosures we make in the reports filed with the Securities and Exchange Commission.
Spectral Molecular Imaging, Inc.
Daniel L. Farkas, Ph.D., 310-858-1670